Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Hitting Cancer Where It Hurts
Two studies in the May 29th issue of Cell, a Cell Press publication, have taken advantage of new technological advances to search for and find previously unknown weaknesses in a hard to treat form of cancer. The discoveries lend new hope in the fight again tumors that are today considered "undruggable."
generic viagra online
Seeking Solutions To The Chronic Nursing Shortage In Canada And The US
The Arthur Labatt Family School of Nursing at The University of Western Ontario has announced a $2 million research chair to address issues surrounding the chronic shortage of registered nurses in Canada and the United States. Dr. Heather Laschinger, Ph.D., was named the first Arthur Labatt Family Nursing Research Chair in Human Re Optimization.
News of the day
CDC Advisory Committee Likely To Place Pregnant Women Near Top Of List For H1N1 Flu Shots
A federal vaccine advisory panel scheduled to meet Wednesday likely will recommend that pregnant women be among the first groups to receive the H1N1 influenza vaccine if a limited number of doses are available, the AP/Atlanta Journal-Constitution reports. The Centers for Disease Control and Prevention usually accepts the recommendations of the panel, called the Advisory Committee on Immunization Practices. According to the AP/Journal-Constitution, health care workers are expected to be the No. 1 priority for receiving the vaccine.For more than 10 years, the panel has recommended that pregnant women get vaccinated for seasonal flu, which can be a threat even to those who are young and healthy. CDC data show that pregnant women, who make up 1% of the U.S. population, have accounted for 6% of H1N1 flu deaths in the country since April, when the pandemic began.British and Swiss health officials have recommended that women consider delaying pregnancies if possible. Most health officials have said that advice oversteps the available evidence, but they have agreed that pregnant women face significant risk from the H1N1 flu. A recent World Health Organization report stated that pregnant women appear to be "at increased risk for severe [H1N1] disease, potentially resulting in spontaneous abortion and/or death, especially during the second and third trimesters of pregnancy." However, WHO has not yet recommended that pregnant women get priority vaccinations. Kevin Ault, an obstetrician at Emory University, said that pregnant women are especially vulnerable because of changes in the lungs and immune system that make it more difficult to overcome respiratory infections (Stobbe, AP/Atlanta Journal-Constitution, 7/28).
Cardiovascular

Study Shows EVISTA(R) Improves Patient Compliance In Osteoporosis Management

Data presented today at the 8th European Congress on Menopause (EMAS) demonstrated that the majority of osteoporosis patients treated with EVISTA(R) (raloxifene) stay on therapy for the first two years. 300 postmenopausal osteoporosis patients received oral treatment with EVISTA(R). Patients were considered compliant if they had taken at least 80% of their medication.[1] Prof. Dr. P. Hadji, University Hospital of Giessen and Marburg GmbH, Marburg, Germany, said that "Results show that at 12, 24 and 36 months 96.4 %, 80.5% and 62% respectively of patients remained on therapy. The mean MPR was 52.8%. Finally 38.5% of all patients were classified adherent". The treatment of osteoporosis among postmenopausal women represents a major public health challenge because long-term therapy is required to prevent fractures and chronic disability.[2] Today"s results highlight the importance of good treatment compliance to help achieve therapeutic benefits for patients, and reduce the burden that osteoporosis places on individuals and the healthcare system.[3] "Poor adherence has a negative effect on patient outcomes, and current treatment with many osteoporosis therapies tends to be suboptimal," commented Prof. Dr. P. Hadji, "However, EVISTA(R) has a long and proven history of patient compliance. Years of research not only confirm that patients adhere to treatment regimens with the drug, but also demonstrate a safety profile that is as strong now as it was when EVISTA(R) first came to market." The data released today at EMAS comes in advance of EVISTA(R)"s 10th anniversary, a turning point that will not go unmarked. Coinciding with World Osteoporosis Day this October, plans are already underway to highlight EVISTA(R)"s continued success as a treatment for postmenopausal women with osteoporosis. Reinhard Bauer, DEO of DAIICHI SANKYO EUROPE, said "DAIICHI SANKYO is delighted to mark the 10th anniversary of EVISTA(R) later this year. The anniversary is intended to raise awareness of the disease and highlight the role that EVISTA(R) has played in transforming osteoporosis management over the years." About EVISTA(R) EVISTA(R) is a type of prescription medication called a Selective Estrogen Receptor Modulator (SERM). It is indicated for the treatment and prevention of osteoporosis in postmenopausal women. EVISTA(R) treats and prevents osteoporosis by reducing the risk of vertebral fractures.[4] EVISTA(R) has been taken by up to 26 million women worldwide, up to 7 million of them were treated in Europe.[5] About DAIICHI SANKYO DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly 5.9 billion EUR in fiscal year 2008, DAIICHI SANKYO is one of the world"s 20 leading pharmaceutical companies. The company"s world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990. The company"s research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are "best" in their class or to create new classes of pharmaceutical drugs. For more information, please visit: http://www.daiichi-sankyo.eu References: [1]. Hadji P, Wetzel K, Ziller V et al. (2009) Compliance during osteoporosis therapy with raloxifene. Poster presented at EMAS 2009 [2]. Turbi C, Herrero-Beaumont G, Acebes JC et al. (2004) Compliance and Satisfaction with Raloxifene Versus Alendronate for the Treatment of Postmenopausal Osteoporosis in Clinical Practice: An Open-Label, Prospective, Nonrandomized, Observational Study. Clin Therap 26; 245-256 [3]. Siris ES, Selby PL, Saag KG et al. (2009) Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe. The American Journal of Medicine (2009) 122, S3-S13 [4]. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD, (2002) Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med.;162(10):1140-3. [5]. Periodic safety Update Report, PSUR 16 Global (10-DEC-2007 TO 09-JUN 2008)/ Data on File DAIICHI SANKYO


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009